Drug Profile
Research programme: metabolic disorder therapeutics - Beacon Discovery/Johnson & Johnson Innovative Medicine
Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Beacon Discovery; Janssen Pharmaceuticals
- Developer Beacon Discovery; Johnson & Johnson Innovative Medicine
- Class Obesity therapies; Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders; Obesity
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 Feb 2022 No recent reports of development identified for research development in Metabolic-disorders in Belgium
- 28 Feb 2022 No recent reports of development identified for research development in Metabolic-disorders in USA